Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature

Refractory cutaneous manifestations constitute a significant unmet need in patients with cutaneous lupus (CLE), even in the setting of systemic lupus erythematosus (SLE) with otherwise good control of inflammatory manifestations. Anifrolumab, an anti-interferon I receptor monoclonal antibody has rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Paolino, Giovanni, Ramirez, Giuseppe A., Calabrese, Chiara, Moroni, Luca, Bianchi, Vittoria Giulia, Bozzolo, Enrica P., Mercuri, Santo Raffaele, Dagna, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669425/
https://www.ncbi.nlm.nih.gov/pubmed/38001905
http://dx.doi.org/10.3390/biomedicines11112904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669425/
https://www.ncbi.nlm.nih.gov/pubmed/38001905
http://dx.doi.org/10.3390/biomedicines11112904

Ejemplares similares